Company Filing History:
Years Active: 2024
Title: The Innovative Mind of Shashank Bharill
Introduction
Shashank Bharill is an accomplished inventor based in Daly City, California, known for his contributions to the field of biomedical innovations. With a keen focus on cytokine signaling and therapeutic applications, he has successfully secured a patent that underscores his expertise and commitment to advancing medical science.
Latest Patents
Shashank Bharill holds a notable patent for "Anti-IL-36 antibodies and methods of use thereof." This invention features binding proteins, including antibodies and antigen-binding fragments, specifically designed to bind to human IL-36 cytokines—namely IL-36α, IL-36β, and IL-36γ. The innovation aims to block IL-36 stimulated signaling pathways, providing a potential therapeutic avenue for various diseases linked to these cytokines. The patent encompasses not only the binding proteins but also the compositions and methods of making and using them effectively in clinical settings.
Career Highlights
Currently, Shashank Bharill is employed at 23andMe, Inc., where he leverages his scientific expertise to explore innovative solutions that intersect genetics and health. His role includes researching and developing new technologies that can improve understanding and treatment of health conditions from a genetic perspective. Bharill's work exemplifies the integration of biotechnology and practical applications in health care.
Collaborations
Throughout his career, Shashank has collaborated with various professionals, including notable coworkers such as Chingwei Vivian Lee and Germaine Fuh-Kelly. These collaborations enhance knowledge exchange and foster a creative environment that leads to groundbreaking innovations in their respective fields.
Conclusion
Shashank Bharill is a prime example of how inventive minds can contribute significantly to science and technology. His patent on Anti-IL-36 antibodies showcases the potential of targeted therapies in combating diseases linked to cytokine dysregulation. As he continues to work at 23andMe, Inc., his future endeavors are sure to leave a lasting impact on the field of biomedical research and innovation.